Peterson Kristine 4

What Happened
Kristine Peterson, a director of Enanta Pharmaceuticals, received a grant (derivative award) for 20,000 shares on March 11, 2026. The reported acquisition price is $0.00, indicating an equity award/option rather than an open‑market purchase or sale. This is a compensation grant, not an immediate purchase or sale of stock.

Key Details

• Transaction date and price: March 11, 2026 — 20,000 shares @ $0.00 (reported as an award/derivative acquisition, code A).
• Shares owned after transaction: Not disclosed in the filing.
• Vesting/other footnote: The award becomes exercisable in substantially equal monthly installments over one year beginning March 11, 2026; the final installment vests no later than the nearest Nasdaq trading day before the 2027 annual meeting.
• Filing timeliness: Form 4 filed March 13, 2026 (appears timely under the Form 4 reporting window).
• Transaction type: Derivative award (option-style grant), not an exercise or sale.

Context
This filing documents a director compensation grant that will vest monthly over 12 months. It does not reflect an exercised option or an open‑market purchase/sale and therefore should be seen as routine director compensation rather than a direct buy or sell signal.